---
title: Phase 2 LYSA study of prednisone, vinblastine, doxorubicin, bendamustine for
  untreated older Hodgkin lymphoma patients
date: '2023-11-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37979133/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231118170613&v=2.17.9.post6+86293ac
source: Blood
description: Older classical Hodgkin lymphoma (cHL) patients require more effective
  and less toxic therapies. In this multicenter, prospective, phase 2 study, we investigated
  a new first-line therapy regimen comprising 6 cycles of prednisone (40 mg/m2 Day
  1-5), vinblastine (6 mg/m2, Day 1), doxorubicin (40 mg/m2, Day 1), bendamustine
  (120 mg/m2, Day 1) (PVAB regimen) every 21 days for newly diagnosed classical HL
  patients aged 61 years or older with an advanced Ann Arbor stage. A Mini Nutritional
  ...
disable_comments: true
---
Older classical Hodgkin lymphoma (cHL) patients require more effective and less toxic therapies. In this multicenter, prospective, phase 2 study, we investigated a new first-line therapy regimen comprising 6 cycles of prednisone (40 mg/m2 Day 1-5), vinblastine (6 mg/m2, Day 1), doxorubicin (40 mg/m2, Day 1), bendamustine (120 mg/m2, Day 1) (PVAB regimen) every 21 days for newly diagnosed classical HL patients aged 61 years or older with an advanced Ann Arbor stage. A Mini Nutritional ...